The efficacy and safety of quinupristin/dalfopristin for the treatment of infections caused by vancomycin-resistant Enterococcus faecium. Synercid Emergency-Use Study Group.

@article{Moellering1999TheEA,
  title={The efficacy and safety of quinupristin/dalfopristin for the treatment of infections caused by vancomycin-resistant Enterococcus faecium. Synercid Emergency-Use Study Group.},
  author={Robert C. Moellering and Peter K. Linden and John W Reinhardt and Emily A. Blumberg and Francois Bompart and George Harrison Talbot},
  journal={The Journal of antimicrobial chemotherapy},
  year={1999},
  volume={44 2},
  pages={251-61}
}
A progressive increase in the incidence of vancomycin resistance in strains of Enterococcus faecium (VREF) has severely constrained treatment options for patients with infection caused by this emerging pathogen. Quinupristin/dalfopristin (Synercid), the first injectable streptogramin antibiotic, is active in vitro against VREF, with an MIC90 of 1.0 mg/L. We studied the clinical efficacy and safety of quinupristin/dalfopristin in the treatment of VREF infection. Two prospective studies were… CONTINUE READING